Eirwen M. Miller, MD

Eirwen M. Miller, MD, discusses the importance of advocating for women in gynecologic oncology on International Women’s Day.

Eirwen M. Miller, MD, discusses updates on antibody-drug conjugates and emerging targets in ovarian cancer.

Eirwen M. Miller, MD, discusses how mirvetuximab soravtansine-gynx in ovarian cancer has bolstered the development of novel ADCs in ovarian cancer.

Eirwen M. Miller, MD, discusses the current treatment landscape of ovarian cancer.

Eirwen M. Miller, MD, discusses the safety and efficacy of veliparib vs other PARP inhibitors used in the treatment of patients with ovarian cancer.

Eirwen M. Miller, MD, discusses the potential utility of sequential PARP inhibition in ovarian cancer.

Eirwen M. Miller, MD, discusses her approach to frontline maintenance therapy in ovarian cancer.